Sign in with Google
Universal Vision Biotechnology (3218 TT): Steady Revenue and Net Profit Growth in 2022;
448 Views31 Mar 2023 11:11
SUMMARY
- Universal Vision Biotechnology (3218 TT) reported continued growth in 2022, with revenue, operating profit, and net profit increasing 33%, 41%, and 43%, YoY, respectively.
- Revenue from high-margin technical service grew 45% YoY, driven by increasing number of refractive and cataract surgeries performed in Taiwan.
- UVB remains on a steady growth path and started 2023 on a strong note. During the first two months of 2023, the company recorded revenue of NT$661M, up 18% YoY.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Toyota Industries (6201 JP): Thoughts on Intrinsic Value
- Foshan Haitian Flavouring & Food (3288 HK): Offering Details & Index Inclusion
- Kioxia IPO Lockup Expiry - US$6.7bn Release, with Shareholders Eager to Sell
- Virgin Australia (VGN AU): Touch & Go for Index Inclusion
- Preferred Shares of Five Major Korean Holdcos - Likely to Close the Gap Further With Common Shares
Top Unpaywalled Insights
More »- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Universal Vision Biotechnology (3218 TT): There Are Plenty of Near-Term Pain Points14 Apr 2025
- Universal Vision Biotechnology (3218 TT): Steady Growth Continued in 1H23 Riding on Strong Demand11 Oct 2023
- Universal Vision Biotechnology (3218 TT): Not Suffering from Myopia; Clear Long-Term Growth Prospect05 Jan 2023
- Universal Vision Biotechnology (3218 TT): 2021 Revenue Growth of 28% Is Outlier Amid COVID-19 Crisis03 Feb 2022
x